Navigation Links
MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Date:12/7/2011

DALLAS, December 7, 2011 /PRNewswire/ --

The report "Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in regions such as North America, & Europe.

Browse market data tables and in-depth TOC on Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020).
http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html
Early buyers will receive 10% customization on reports.

In acute lymphocytic leukemia, the body rapidly produces a large number of immature white blood cells, called lymphocytes. These immature white blood cells replace normal cells in the bone marrow. This type of cancer accounts for about 12% of the total leukemia. This type of cancer can be sub-categorized into childhood acute lymphocytic leukemia and adult acute lymphocytic leukemia.

Acute lymphocytic leukemia (ALL) is the most common type of leukemia in young children. This disease also affects adults, especially those aged 65 and older. Standard treatments involve chemotherapy and radiotherapy. The survival rates vary by age: 85% in children and 50% in adults. Subtypes include precursor B acute lymphocytic leukemia, precursor T acute lymphocytic leukemia, Burkitt leukemia, and acute biphenotypic leukemia.

The acute lymphocytic leukemia therapeutics market [ http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html ] was valued at $1.96 billion in 2010 and is expected to reach $3.88 billion by 2020, at a CAGR of 5.21% between 2015 and 2020. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen. The chemotherapy drug regimens were dominated by Hyper-CVAD regimen sales, totaling $1.8 billion and linker regimen sales totaling $1.13 billion sales in acute lymphocytic leukemia market.

According to WHO, acute lymphocytic leukemia is expected to be more prominent in the in more developed countries and higher socioeconomic groups such as North America and European countries due to genetic factor. Other causes like environmental factor and exposure to high doses of radiation are also the causative factors of all the types of acute lymphocytic leukemia.

The U.S. dominates the North American leukemia drug market with a 90% share; whereas Germany dominates the European market with 35% share.

Major players in the market include Ambit Biosciences Inc. (U.S.), ERYtech Pharma (France), Talon Therapeutic Inc. (U.S.), and Genzyme Corporation. (U.S.).

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical, pharmaceuticals [ http://www.marketsandmarkets.com/pharmaceutical-market-research-3.html ], semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com.

Contact:
Mr. Rohan
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com
MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/
http://www.sandlerresearch.org/
http://twitter.com/marketsmarkets



'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
2. MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014
3. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 2014
4. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
5. MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014
6. MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014
7. MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 2015
8. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
11. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Franz Inc ., ... development tools, and market leader for Semantic Graph Database technology, today ... within the most effective system for developing and deploying applications to solve the ...
(Date:4/25/2017)... GREENVILLE, SC (PRWEB) , ... April 25, 2017 ... ... SC-based Piedmont Physical Medicine & Rehabilitation, P.A. , proudly announced today that ... will officially commence his duties on May 15, 2017. , Dr. Terzella completed ...
(Date:4/24/2017)... ... April 24, 2017 , ... It is well established that ... the broad application of this cellular target engagement concept to drug discovery has ... thermal stabilization assays are valuable methods for particular applications, but they can require ...
(Date:4/21/2017)... ... April 21, 2017 , ... Having worked on the design of ... pleased to introduce it to top lab design architects from around the country at ... VP of Industrial Design and Engineering Greg Casey will be at the show, where ...
Breaking Biology Technology:
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOGĀ“s multi-biometrics system.   Continue ... ...
Breaking Biology News(10 mins):